Charles River And Autobahn Labs Establish Partnership To Accelerate Academic Discoveries Into Novel Therapeutics; Charles River To Make Equity Investment In Autobahn Labs; Chief Scientific Officer Justin Bryans Named To Autobahn's Board Of Directors
Charles River And Autobahn Labs Establish Partnership To Accelerate Academic Discoveries Into Novel Therapeutics; Charles River To Make Equity Investment In Autobahn Labs; Chief Scientific Officer Justin Bryans Named To Autobahn's Board Of Directors
查爾斯河實驗室和Autobahn Labs建立合作伙伴關係，加速將學術發現轉化爲新型治療藥物；查爾斯河實驗室將對Autobahn Labs進行股權投資；首席科學家Justin Bryans被任命爲Autobahn的董事會成員。
- Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics
- Under the agreement, Charles River will make an equity investment in Autobahn Labs
- Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors
- 協議確立了查爾斯河實驗室作爲Autobahn Labs的優選合作伙伴，利用藥物研發能力加速學術發現成果轉化爲新型治療藥物
- 根據協議，查爾斯河實驗室將對Autobahn Labs進行股權投資
- 查爾斯河實驗室的首席科學家賈斯汀·布賴恩斯被任命爲Autobahn的董事會成員
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。